Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Antiviral Chemistry and Chemotherapy
ISSN 0956-3202 · eISSN 2040-2066 · SAGE · United Kingdom
Antiviral Chemistry and Chemotherapy: fully open access; APC about USD 1,500; review about 15 weeks (community reports); indexed in Scopus.
Scope
Aims, scope and focus
Antiviral Chemistry and Chemotherapy is published by SAGE. By OpenAlex counts of its recent articles, its largest topics are HIV/AIDS drug development and treatment, HIV Research and Treatment and Herpesvirus Infections and Treatments, together about 44.8% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Editor-in-chief Andrea BrancalePublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 21, United Kingdom 7, Italy 6, Belgium 6, Japan 3 (59 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- HIV/AIDS drug development and treatmentMedicine22.1%
- HIV Research and TreatmentImmunology and Microbiology12%
- Herpesvirus Infections and TreatmentsMedicine10.7%
- Cytomegalovirus and herpesvirus researchMedicine5.1%
- Synthesis and Characterization of Heterocyclic CompoundsChemistry5%
- Hepatitis C virus researchMedicine3.6%
- DNA and Nucleic Acid ChemistryBiochemistry, Genetics and Molecular Biology3.3%
- Synthesis and biological activityChemistry3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology | Q3 | 212/321 | 34th |
| Virology | Q3 | 61/86 | 29th |
| Drug Discovery | Q3 | 113/156 | 27th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 2.8LetPub ·
- SJR 2026-06
- 0.33LetPub ·
- SNIP 2026-06
- 0.58LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 607OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 1,014 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 421 |
| 2025 | 0 | 0 | 633 |
| 2024 | 0 | 0 | 799 |
| 2023 | 2 | 2 | 802 |
| 2022 | 6 | 6 | 1,103 |
| 2021 | 9 | 9 | 1,191 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 15 weeksLetPub ·
- Peer review
- Blind peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 1,500 | — | — | |
| LetPub | USD 1,500 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- First submission
- Free format: the journal's layout is not required
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 0956-3202
- Electronic ISSN
- 2040-2066
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Antiviral Chemistry and Chemotherapy
How long does peer review take at Antiviral Chemistry and Chemotherapy?
Authors report an average review time of about 15 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Antiviral Chemistry and Chemotherapy based?
Of the 59 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (21), United Kingdom (7) and Italy (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Antiviral Chemistry and Chemotherapy?
According to LetPub and DOAJ records, Antiviral Chemistry and Chemotherapy is indexed in Scopus.
Is Antiviral Chemistry and Chemotherapy open access, and what is the APC?
Antiviral Chemistry and Chemotherapy is a fully open-access journal. APC about USD 1,500.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .